Skip to main content
Clinical Trials/NCT04044625
NCT04044625
Completed
Not Applicable

Effects of High-intensity Versus Low-intensity Noninvasive Positive Pressure Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial

Beijing Chao Yang Hospital1 site in 1 country24 target enrollmentSeptember 30, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Sponsor
Beijing Chao Yang Hospital
Enrollment
24
Locations
1
Primary Endpoint
PaCO2 measured at 24 hours after enrollment
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This study aims to investigate the effects of high-intensity noninvasive positive pressure ventilation (NPPV), as compared with low-intensity NPPV, on hypercapnia, consciousness, inspiratory muscle effort, dyspnea, NPPV tolerance, inflammatory response, adverse events and other outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease.

Registry
clinicaltrials.gov
Start Date
September 30, 2019
End Date
June 16, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Beijing Chao Yang Hospital
Responsible Party
Principal Investigator
Principal Investigator

Zujin Luo

Principal Investigator

Beijing Chao Yang Hospital

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of COPD according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease in 2019
  • Presence of acute exacerbation
  • Arterial pH \<7.35 with arterial carbon dioxide tension (PaCO2) \>45 mmHg on room air or supplemental oxygen
  • PaCO2 \>45 mmHg following low-intensity NPPV of ≥6 hours

Exclusion Criteria

  • Age \<18 years
  • Excessive amount of respiratory secretions or weak cough
  • Upper airway obstruction
  • Recent oral, facial, or cranial trauma or surgery; recent gastric or esophageal surgery
  • Potential risk factors for restrictive ventilatory dysfunction (eg, consolidation or removal of at least one pulmonary lobe, massive pleural effusion, chest wall deformity, continuous strapping with thoracic or abdominal bandage, and severe abdominal distention)
  • Active upper gastrointestinal bleeding
  • Cardiac or respiratory arrest
  • Arterial oxygen tension/fraction of inspired oxygen \<100 mmHg
  • Pneumothorax
  • Severe ventricular arrhythmia or myocardial ischemia

Outcomes

Primary Outcomes

PaCO2 measured at 24 hours after enrollment

Time Frame: 24 hours

PaCO2 measured at 24 hours after enrollment.

Secondary Outcomes

  • PaCO2 measured at 2 hours after enrollment(2 hours)
  • PaCO2 measured at 6 hours after enrollment(6 hours)
  • PaCO2 measured at 48 hours after enrollment(48 hours)
  • PaCO2 measured at 72 hours after enrollment(72 hours)
  • Glasgow coma scale score(72 hours)
  • ΔPes(72 hours)
  • Dyspnea score(72 hours)
  • NPPV tolerance score(72 hours)
  • Plasma level of TNF-α(72 hours)
  • Plasma level of I-1β(72 hours)
  • Plasma level of IL-6(72 hours)
  • Plasma level of IL-8(72 hours)
  • Plasma level of IL-10(72 hours)

Study Sites (1)

Loading locations...

Similar Trials